Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hsp90 Inhibitor
100%
Heat Shock Protein 90 (Hsp90)
100%
Preclinical Evaluation
100%
Heat Shock Protein 90 Inhibitor
75%
Alzheime's Disease
75%
Alzheimer's Disease
75%
Tau Protein
50%
17-AAG
50%
Neurodegenerative Disorders
50%
Chaperone
50%
Waza
25%
Cancer Treatment
25%
Hereditary mutations
25%
Tau Accumulation
25%
RTg4510
25%
Parkinson's Disease
25%
Intraneuronal
25%
Memory Loss
25%
Tau Degradation
25%
Phospho-tau
25%
Affected Area
25%
17-allylamino-17-demethoxygeldanamycin
25%
Heat Shock
25%
In-Cell Western Assay
25%
Protein Species
25%
Spinobulbar muscular Atrophy
25%
Microtubule-associated Protein tau Gene
25%
Mutant Forms
25%
Human tau
25%
Androgen Receptor
25%
High-affinity State
25%
Motor Impairment
25%
Transgenic Mouse Model
25%
Molecular Chaperone
25%
Frontotemporal Dementia
25%
Neurological Disorders
25%
Tetracycline Operator
25%
Misfolding
25%
Tumor Cells
25%
Pathologic
25%
Alzheimer's Disease Brain
25%
Systemic Administration
25%
Spinal muscular Atrophy
25%
P301L
25%
Phosphorylated tau
25%
Novel Inhibitors
25%
Misfolded Proteins
25%
Blood-brain Barrier
25%
Brain Tissue
25%
Well Tolerated
25%
Binding Affinity
25%
Geldanamycin
25%
Abnormal Protein
25%
Mouse Model
25%
Biochemistry, Genetics and Molecular Biology
Hsp90 Inhibitor
100%
Tau
100%
Hsp90
66%
Heat Shock Protein 90 Inhibitor
50%
Tau Protein
50%
Mouse Model
33%
Binding Affinity
16%
Lifespan
16%
Geldanamycin
16%
Androgen Receptor
16%
Heat Shock
16%
Blood Brain Barrier
16%
Transgenic Mouse
16%
Proteasome
16%
Chaperone
16%
Chaperone Protein
8%
Pharmacology, Toxicology and Pharmaceutical Science
Heat Shock Protein 90 Inhibitor
100%
Alzheimer's Disease
66%
Tau Protein
50%
Tanespimycin
50%
Mouse Model
33%
Chaperone
33%
Proteasome
16%
Motor Dysfunction
16%
Transgenic Mouse
16%
Parkinson's Disease
16%
Systemic Administration
16%
Tetracycline
16%
Kennedy Disease
16%
Androgen Receptor
16%
Neoplasm
16%
Malignant Neoplasm
16%
Frontotemporal Dementia
16%
Geldanamycin
16%
Blood-Brain Barrier
16%